Who are gemcitabine, cisplatin and bevacizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabine-cisplatin-and-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

gemcitabine, cisplatin and bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

gemcitabine, cisplatin and bevacizumab (gemcitabine, cisplatin and bevacizumab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy with anti-angiogenic monoclonal antibody. Area: Oncology.

marketed Combination chemotherapy with anti-angiogenic monoclonal antibody DNA (gemcitabine, cisplatin); VEGF (bevacizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

gemcitabine, cisplatin and bevacizumab (gemcitabine, cisplatin and bevacizumab) — Fundacion Clinic per a la Recerca Biomédica. This combination uses gemcitabine and cisplatin as chemotherapy agents to damage cancer cell DNA, while bevacizumab blocks tumor blood vessel formation to inhibit cancer growth.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
gemcitabine, cisplatin and bevacizumab TARGET	gemcitabine, cisplatin and bevacizumab	Fundacion Clinic per a la Recerca Biomédica	marketed	Combination chemotherapy with anti-angiogenic monoclonal antibody	DNA (gemcitabine, cisplatin); VEGF (bevacizumab)
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine	Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine	Borstkanker Onderzoek Groep	phase 3	Combination chemotherapy with anti-angiogenic monoclonal antibody	Multiple: microtubules (paclitaxel), VEGF (bevacizumab), DNA (doxorubicin), thymidylate synthase (capecitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy with anti-angiogenic monoclonal antibody class)

Borstkanker Onderzoek Groep · 1 drug in this class
Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). gemcitabine, cisplatin and bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-cisplatin-and-bevacizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab